Shots:
- Galderma has reported OLYMPIA LTE study data assessing Nemluvio in 508 pts with prurigo nodularis up to 4yrs., from the P-II trial & the P-III (OLYMPIA 1 & 2) trials
- At Wk. 148, >70% of pts had clear or almost clear lesions per IGA score, >85% achieved ≥75% of healed lesions by prurigo activity score, over 85% reported meaningful itch reduction, & ~75% reached an itch-free or nearly itch-free state
- Additionally, ~90% of pts achieved meaningful QoL improvement, with over 50% achieving a DLQI score of 0-1, while Nemluvio’s long-term safety profile remained consistent with prior data & established findings in prurigo nodularis; data to be presented at 2026 Winter Clinical Miami
Ref: Businesswire | Image: Galderma | Press Release
Related News: Galderma Initiates P-II Studies of Nemolizumab for Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
